RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm, open-labal, phase II clinical study with a planned
enrollment of 31 patients with HER2-overexpressing unresectable locally advanced or
metastatic biliary carcinoma who had failed previous treatment. The efficacy and safety of
the study were evaluated according to RECIST V1.1.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University